Similarly, in BRAF-mutant melanoma, PDX models resistant to BRAF and MEK inhibitors exhibited alternative activation of the mammalian target of rapamycin (mTOR) pathway, suggesting that mTOR inhibitors could be a viable treatment option for these patients [238]. This evidence concerns the gene MTOR and melanoma.